To assess the impact of SRC‐1 inhibition on HCC cell invasiveness, we selected Bufalin, a well‐known SRC‐1 inhibitor, for treatment in both HCC cells and metastasis tumour mouse models. Here, SRC is linked to hepatocellular carcinoma.